|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0023981,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0078257,
umls-concept:C0205132,
umls-concept:C0246415,
umls-concept:C0282460,
umls-concept:C0332174,
umls-concept:C1654637,
umls-concept:C1709323
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-5-18
|
|
pubmed:abstractText |
In previous phase I to III studies docetaxel and vinorelbine have shown promising activity in androgen independent prostate cancer. In the present trial we assessed the efficacy and tolerability of single agent low dose docetaxel vs vinorelbine in patients with advanced androgen independent prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
pubmed-author:AlbrechtWalterW,
pubmed-author:EisenmengerMichaelM,
pubmed-author:ElandtKatarzynaK,
pubmed-author:HöltlWolfgangW,
pubmed-author:HorakPeterP,
pubmed-author:KrainerMichaelM,
pubmed-author:ReibenweinJochenJ,
pubmed-author:SchramekPaulP,
pubmed-author:StacklWalterW,
pubmed-author:TomekSandraS,
pubmed-author:ZielinskiChristophC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
177
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2141-5; discussion 2145
|
|
pubmed:meshHeading |
pubmed-meshheading:17509302-Aged,
pubmed-meshheading:17509302-Aged, 80 and over,
pubmed-meshheading:17509302-Antineoplastic Agents,
pubmed-meshheading:17509302-Drug Administration Schedule,
pubmed-meshheading:17509302-Humans,
pubmed-meshheading:17509302-Male,
pubmed-meshheading:17509302-Middle Aged,
pubmed-meshheading:17509302-Prospective Studies,
pubmed-meshheading:17509302-Prostate-Specific Antigen,
pubmed-meshheading:17509302-Prostatic Neoplasms,
pubmed-meshheading:17509302-Taxoids,
pubmed-meshheading:17509302-Treatment Outcome,
pubmed-meshheading:17509302-Vinblastine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine I, Division of Oncology and Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria. michael.krainer@meduniwien.ac.at
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Clinical Trial, Phase II
|
